However, a genuine predictive value of p-70S6K for lapatinib would necessitate testing this biomarker also in lapatinib-untreated patients, to exclude its possible favorable prognostic impact shown previously in early ERα-positive breast cancer [49]. Here, ESR1 is linked to breast carcinoma.